首页 > 最新文献

EBioMedicine最新文献

英文 中文
Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines. 通过刺激反应性纳米药物的协同化学免疫治疗逆转三阴性乳腺癌中腺苷介导的免疫抑制。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2025-12-05 DOI: 10.1016/j.ebiom.2025.106059
Xinying Cheng, Hao Cai, Xue Li, Yuxin Zhang, Siying Li, Yunkun Li, Na Hu, Su Lui, Jing Jing, Qiyong Gong, Kui Luo

Background: Chemotherapy remains the first-line treatment for triple-negative breast cancer (TNBC). Anthracycline chemotherapeutics, such as epirubicin (EPI), not only kill tumor cells but also induce immunogenic cell death (ICD). However, accumulated extracellular adenosine triphosphate (eATP) during ICD is converted to adenosine, triggering immunosuppression via adenosine receptor signalling. To address this issue, co-administration of EPI with adenosine receptor antagonists could remodel the immunosuppressive tumor microenvironment and potentiate antitumor immunity.

Methods: The effect of the expression level of adenosine receptors on the immune microenvironment of TNBC was assessed by integrating bioinformatic analysis of public databases with immunofluorescence staining of TNBC clinical samples. Four polymeric prodrugs of EPI were synthesised, and their delivery performances were assessed. A nanomedicine with pH/cathepsin B (CTSB)-responsiveness for co-delivery of EPI and AB928 (an adenosine receptor antagonist) was constructed. The cellular experiments and 4T1 tumor-bearing mice model were employed to evaluate antitumor efficacy.

Findings: Bioinformatic analyses and immunofluorescence staining of TNBC clinical samples supported the rationale for combining ICD-inducing chemotherapeutic agents with adenosine receptor antagonists. The polymeric prodrug of EPI with an optimal delivery efficiency was selected to encapsulate AB928. The constructed nanomedicine for EPI/AB928 co-delivery enhanced antitumor immune responses by effectively inhibiting adenosine-A2A receptor/A2B receptor (A2AR/A2BR) signalling pathways and reversing adenosine-mediated immunosuppression.

Interpretation: Co-delivery of an ICD inducer (EPI) and an adenosine receptor antagonist (AB928) is realised in a stimuli-responsive nanomedicine to address immunosuppression induced by adenosine, thereby enhancing ICD effects and synergistically reprogramming the immunosuppressive tumor microenvironment.

Funding: See Acknowledgements.

背景:化疗仍然是三阴性乳腺癌(TNBC)的一线治疗方法。蒽环类化疗药物,如表柔比星(EPI),不仅能杀死肿瘤细胞,还能诱导免疫原性细胞死亡(ICD)。然而,ICD期间积累的细胞外三磷酸腺苷(eATP)转化为腺苷,通过腺苷受体信号传导引发免疫抑制。为了解决这一问题,EPI与腺苷受体拮抗剂联合使用可以重塑免疫抑制的肿瘤微环境,增强抗肿瘤免疫。方法:采用公共数据库生物信息学分析与TNBC临床标本免疫荧光染色相结合的方法,评估腺苷受体表达水平对TNBC免疫微环境的影响。合成了四种EPI高分子前药,并对其递送性能进行了评价。构建了一种具有pH/组织蛋白酶B (CTSB)响应性的纳米药物,用于联合递送EPI和腺苷受体拮抗剂AB928。采用细胞实验和4T1荷瘤小鼠模型评价其抗肿瘤效果。结果:TNBC临床样本的生物信息学分析和免疫荧光染色支持icd诱导化疗药物与腺苷受体拮抗剂联合使用的基本原理。选择最优给药效率的EPI高分子前药包封AB928。构建的EPI/AB928共递送纳米药物通过有效抑制腺苷- a2a受体/A2B受体(A2AR/A2BR)信号通路和逆转腺苷介导的免疫抑制,增强抗肿瘤免疫应答。解释:在刺激反应性纳米药物中实现了ICD诱导剂(EPI)和腺苷受体拮抗剂(AB928)的共同递送,以解决腺苷诱导的免疫抑制问题,从而增强ICD效果并协同重新编程免疫抑制肿瘤微环境。资助:见致谢。
{"title":"Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines.","authors":"Xinying Cheng, Hao Cai, Xue Li, Yuxin Zhang, Siying Li, Yunkun Li, Na Hu, Su Lui, Jing Jing, Qiyong Gong, Kui Luo","doi":"10.1016/j.ebiom.2025.106059","DOIUrl":"10.1016/j.ebiom.2025.106059","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy remains the first-line treatment for triple-negative breast cancer (TNBC). Anthracycline chemotherapeutics, such as epirubicin (EPI), not only kill tumor cells but also induce immunogenic cell death (ICD). However, accumulated extracellular adenosine triphosphate (eATP) during ICD is converted to adenosine, triggering immunosuppression via adenosine receptor signalling. To address this issue, co-administration of EPI with adenosine receptor antagonists could remodel the immunosuppressive tumor microenvironment and potentiate antitumor immunity.</p><p><strong>Methods: </strong>The effect of the expression level of adenosine receptors on the immune microenvironment of TNBC was assessed by integrating bioinformatic analysis of public databases with immunofluorescence staining of TNBC clinical samples. Four polymeric prodrugs of EPI were synthesised, and their delivery performances were assessed. A nanomedicine with pH/cathepsin B (CTSB)-responsiveness for co-delivery of EPI and AB928 (an adenosine receptor antagonist) was constructed. The cellular experiments and 4T1 tumor-bearing mice model were employed to evaluate antitumor efficacy.</p><p><strong>Findings: </strong>Bioinformatic analyses and immunofluorescence staining of TNBC clinical samples supported the rationale for combining ICD-inducing chemotherapeutic agents with adenosine receptor antagonists. The polymeric prodrug of EPI with an optimal delivery efficiency was selected to encapsulate AB928. The constructed nanomedicine for EPI/AB928 co-delivery enhanced antitumor immune responses by effectively inhibiting adenosine-A2A receptor/A2B receptor (A2AR/A2BR) signalling pathways and reversing adenosine-mediated immunosuppression.</p><p><strong>Interpretation: </strong>Co-delivery of an ICD inducer (EPI) and an adenosine receptor antagonist (AB928) is realised in a stimuli-responsive nanomedicine to address immunosuppression induced by adenosine, thereby enhancing ICD effects and synergistically reprogramming the immunosuppressive tumor microenvironment.</p><p><strong>Funding: </strong>See Acknowledgements.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106059"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12721312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Projected extreme temperature event-attributable dementia deaths in China: a climate-ageing-adaptation framework. 中国极端温度事件导致的痴呆死亡预测:气候老龄化适应框架。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2025-12-09 DOI: 10.1016/j.ebiom.2025.106072
Rui Zhang, Yonghong Li, Huan Zheng, Mulei Chen, Jia Zhao, Yiming Hu, Ainan Jia, Qing Guo, Songwang Wang, Liusen Wang, Ran Niu, Chaonan Wang, Qinmei Han, Xuejie Du, Lizhu Jin, Shaoqiong Li, Qiang Chen, Yujie Meng, Siyuan Wu, Bo Lu, Rong Zhao, Peng Bi, Jing Wu

Background: Climate change is increasing health risks worldwide, but how extreme temperature events affect Alzheimer's disease and other dementias (ADD) remains poorly understood. We aimed to project future extreme temperature event-attributable ADD deaths in China, accounting for the combined effects of climate change, population ageing, and adaptation methods.

Methods: We analysed 399,036 ADD deaths among adults aged ≥60 years in China during 2013-2020, using a time-stratified case-crossover design to estimate ADD mortality risks associated with extreme temperature events. We subsequently developed an integrated climate-ageing-adaptation framework that combined exposure-response functions, high-resolution climate projections, and demographic forecasts. Using this framework, we projected county-level ADD deaths attributable to heatwaves and cold spells among individuals aged ≥60 years across China under multiple SSP-RCP and adaptation scenarios for the 2030s, 2050s, and 2080s FINDINGS: Without adaptation, ADD heatwave-attributable deaths are projected to rise sharply, especially under rapid socioeconomic development with high greenhouse gas emissions scenario (SSP5-RCP8.5) in the 2080s, which reach 59,088-an 11-fold (+1003%) increase comparing to 2010s levels. Cold spell-attributable deaths generally decline but reductions are insufficient to offset the sharp rise in heatwave mortality, leading to a net increase in total attributable deaths. Adaptation strategies could avert up to 76.4% of heatwave-attributable deaths compared to no-adaptation scenario.

Interpretation: The convergence of climate change and population ageing is projected to substantially magnify dementia-related mortality in China. Under SSP5-RCP8.5, deaths attributable to extreme temperature events are projected to reach unprecedented levels by the end of the 21st century, especially without adaptation measures. These findings underscore the urgent need for massive greenhouse gases emission reductions alongside balanced, region-specific adaptation measures, and highlight dementia care as an essential component of climate resilience planning. Our study provides guidance for designing climate-resilient public health policies, particularly for ageing populations in climate-vulnerable counties and regions.

Funding: This work was supported by the Science and Technology Fundamental Resources Investigation Program of China [2017FY101201, 2017FY101206], and the National Foundation for Australia-China Relations of Australia [6016294].

背景:气候变化正在增加全球范围内的健康风险,但极端温度事件如何影响阿尔茨海默病和其他痴呆症(ADD)仍然知之甚少。考虑到气候变化、人口老龄化和适应方法的综合影响,我们旨在预测中国未来由极端温度事件导致的ADD死亡。方法:我们分析了2013-2020年期间中国年龄≥60岁成人中399,036例ADD死亡病例,采用时间分层病例交叉设计来估计极端温度事件相关的ADD死亡风险。随后,我们开发了一个综合的气候老龄化适应框架,该框架结合了暴露响应函数、高分辨率气候预测和人口预测。利用这一框架,我们在多个SSP-RCP和2030年代、2050年代和2080年代的适应情景下,预测了中国60岁以上人群中因热浪和寒流导致的ADD死亡。如果不采取适应措施,预计ADD热浪导致的死亡人数将急剧上升,特别是在21世纪80年代社会经济快速发展和高温室气体排放情景(SSP5-RCP8.5)的情况下,这一数字将达到59,088——比2010年代的水平增加11倍(+1003%)。寒潮导致的死亡人数普遍下降,但减少的人数不足以抵消热浪死亡率的急剧上升,导致可归因于的死亡总人数净增加。与不适应情景相比,适应战略可以避免高达76.4%的热浪导致的死亡。解释:气候变化和人口老龄化的趋同预计将大大增加中国的痴呆症相关死亡率。根据SSP5-RCP8.5,预计到21世纪末,极端温度事件造成的死亡人数将达到前所未有的水平,特别是在不采取适应措施的情况下。这些研究结果强调,迫切需要大规模减少温室气体排放,同时采取平衡的、针对特定地区的适应措施,并强调痴呆症护理是气候适应规划的重要组成部分。我们的研究为设计具有气候适应性的公共卫生政策提供了指导,特别是为易受气候影响的国家和地区的老龄化人口提供了指导。基金资助:中国科技基础资源调查计划项目[2017fy101201,2017fy101206]和澳大利亚中澳关系国家基金会[6016294]资助。
{"title":"Projected extreme temperature event-attributable dementia deaths in China: a climate-ageing-adaptation framework.","authors":"Rui Zhang, Yonghong Li, Huan Zheng, Mulei Chen, Jia Zhao, Yiming Hu, Ainan Jia, Qing Guo, Songwang Wang, Liusen Wang, Ran Niu, Chaonan Wang, Qinmei Han, Xuejie Du, Lizhu Jin, Shaoqiong Li, Qiang Chen, Yujie Meng, Siyuan Wu, Bo Lu, Rong Zhao, Peng Bi, Jing Wu","doi":"10.1016/j.ebiom.2025.106072","DOIUrl":"10.1016/j.ebiom.2025.106072","url":null,"abstract":"<p><strong>Background: </strong>Climate change is increasing health risks worldwide, but how extreme temperature events affect Alzheimer's disease and other dementias (ADD) remains poorly understood. We aimed to project future extreme temperature event-attributable ADD deaths in China, accounting for the combined effects of climate change, population ageing, and adaptation methods.</p><p><strong>Methods: </strong>We analysed 399,036 ADD deaths among adults aged ≥60 years in China during 2013-2020, using a time-stratified case-crossover design to estimate ADD mortality risks associated with extreme temperature events. We subsequently developed an integrated climate-ageing-adaptation framework that combined exposure-response functions, high-resolution climate projections, and demographic forecasts. Using this framework, we projected county-level ADD deaths attributable to heatwaves and cold spells among individuals aged ≥60 years across China under multiple SSP-RCP and adaptation scenarios for the 2030s, 2050s, and 2080s FINDINGS: Without adaptation, ADD heatwave-attributable deaths are projected to rise sharply, especially under rapid socioeconomic development with high greenhouse gas emissions scenario (SSP5-RCP8.5) in the 2080s, which reach 59,088-an 11-fold (+1003%) increase comparing to 2010s levels. Cold spell-attributable deaths generally decline but reductions are insufficient to offset the sharp rise in heatwave mortality, leading to a net increase in total attributable deaths. Adaptation strategies could avert up to 76.4% of heatwave-attributable deaths compared to no-adaptation scenario.</p><p><strong>Interpretation: </strong>The convergence of climate change and population ageing is projected to substantially magnify dementia-related mortality in China. Under SSP5-RCP8.5, deaths attributable to extreme temperature events are projected to reach unprecedented levels by the end of the 21st century, especially without adaptation measures. These findings underscore the urgent need for massive greenhouse gases emission reductions alongside balanced, region-specific adaptation measures, and highlight dementia care as an essential component of climate resilience planning. Our study provides guidance for designing climate-resilient public health policies, particularly for ageing populations in climate-vulnerable counties and regions.</p><p><strong>Funding: </strong>This work was supported by the Science and Technology Fundamental Resources Investigation Program of China [2017FY101201, 2017FY101206], and the National Foundation for Australia-China Relations of Australia [6016294].</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106072"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12753258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145721693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment. 肺动脉高压的男性生存劣势:独立于病因、年龄、疾病严重程度、合并症和治疗。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2025-12-16 DOI: 10.1016/j.ebiom.2025.106063
Athiththan Yogeswaran, Jeffrey S Annis, Meike Fünderich, Jochen Wilhelm, David G Kiely, Luke Howard, Allan Lawrie, Martin R Wilkins, Aparna Balasubramanian, Paul M Hassoun, Ziad Konswa, Christina A Eichstaedt, Ekkehard Grünig, Andrew J Sweatt, Roham T Zamanian, Gabor Kovacs, Horst Olschewski, Mona Lichtblau, Silvia Ulrich, Thenappan Thenappan, Imad Al Ghouleh, Stephen Y Chan, Jean Elwing, Arun Jose, John Cannon, Joanna Pepke-Zaba, Robert Frantz, Yuriy Sirenko, Olena Torbas, Sandeep Sahay, Zhenguo Zhai, Zhu Zhang, Alexandra Arvanitaki, George Giannakoulas, Marlize Frauendorf, Paul G Williams, Keiichiro Kuronuma, Hiromi Matsubara, Stefano Ghio, Laura Scelsi, Hanni Sabbour, Khaled Saleh, Anastasia Anthi, Effrosyni Dima, Raphael W Majeed, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Khodr Tello, Hector R Cajigas, Evan Brittain, Werner Seeger

Background: Sex-based differences in morbidity and mortality in pulmonary hypertension (PH) are underexplored, yet understanding these differences is vital for improving clinical management. This study investigates the influence of sex on survival of patients with PH in dependency of various disease conditions.

Methods: The PVRI GoDeep meta-registry integrates data from international PH registries, of which we analysed 21,123 incident hemodynamically fully characterised patients with PH. Survival analyses employed Kaplan-Meier and Cox proportional hazards models, adjusted for confounders and subjected to sensitivity analyses.

Findings: Male patients consistently showed significantly higher mortality than females across the overall PH population (hazard ratio 1.36 [1.23, 1.50] after adjustment) and within PAH and non-PAH groups. These sex differences in survival persisted regardless of P(A)H severities, age and obesity, cardiovascular diseases, and PAH-specific therapies. The male survival disadvantage was noted across low-, intermediate-, and high-risk groups of the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores, but not the REVEAL 2.0 risk score, which incorporates male sex as non-modifiable factor. Stratification by race revealed that male sex was associated with worse survival in White patients, but not in Black or Asian patients with PH.

Interpretation: Male patients with PH exhibit significantly higher mortality risks than females across both PAH and non-PAH PH groups. This disparity persists regardless of PH severity, underlying cause, age, obesity, comorbidities, or treatment status, though race might modify the observed risk difference. These insights provide new avenues for investigating underlying mechanisms and suggest including male sex as an independent factor in clinical risk assessment tools.

Funding: This work is funded by the Pulmonary Vascular Research Institute (PVRI) and the Cardiovascular Medical Research and Education Fund (CMREF), NIH.

背景:肺动脉高压(PH)发病率和死亡率的性别差异尚未得到充分研究,但了解这些差异对于改善临床管理至关重要。本研究探讨性别对PH依赖于各种疾病的患者生存的影响。方法:PVRI GoDeep meta-registry整合了来自国际PH登记处的数据,其中我们分析了21,123例血液动力学完全特征的PH患者。生存分析采用Kaplan-Meier和Cox比例风险模型,对混杂因素进行了调整,并进行了敏感性分析。研究结果:在整个PH人群中,以及在PAH和非PAH组中,男性患者的死亡率均明显高于女性(调整后的危险比为1.36[1.23,1.50])。无论P(A)H严重程度、年龄和肥胖、心血管疾病和pah特异性治疗,这些生存的性别差异都持续存在。在ESC/ERS 2022、REVEAL life 2和COMPERA 4层评分中,低、中、高风险组均存在男性生存劣势,但在将男性性别作为不可修改因素的REVEAL 2.0风险评分中没有。种族分层显示男性与白人PH患者的生存率较差相关,但与黑人或亚洲PH患者无关。解释:在PAH和非PAH PH组中,男性PH患者的死亡风险明显高于女性。尽管种族可能会改变观察到的风险差异,但无论PH严重程度、潜在原因、年龄、肥胖、合并症或治疗状态如何,这种差异都存在。这些见解为研究潜在机制提供了新的途径,并建议将男性性别作为临床风险评估工具的独立因素。资助:本研究由美国国立卫生研究院肺血管研究所(PVRI)和心血管医学研究与教育基金(CMREF)资助。
{"title":"Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment.","authors":"Athiththan Yogeswaran, Jeffrey S Annis, Meike Fünderich, Jochen Wilhelm, David G Kiely, Luke Howard, Allan Lawrie, Martin R Wilkins, Aparna Balasubramanian, Paul M Hassoun, Ziad Konswa, Christina A Eichstaedt, Ekkehard Grünig, Andrew J Sweatt, Roham T Zamanian, Gabor Kovacs, Horst Olschewski, Mona Lichtblau, Silvia Ulrich, Thenappan Thenappan, Imad Al Ghouleh, Stephen Y Chan, Jean Elwing, Arun Jose, John Cannon, Joanna Pepke-Zaba, Robert Frantz, Yuriy Sirenko, Olena Torbas, Sandeep Sahay, Zhenguo Zhai, Zhu Zhang, Alexandra Arvanitaki, George Giannakoulas, Marlize Frauendorf, Paul G Williams, Keiichiro Kuronuma, Hiromi Matsubara, Stefano Ghio, Laura Scelsi, Hanni Sabbour, Khaled Saleh, Anastasia Anthi, Effrosyni Dima, Raphael W Majeed, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Khodr Tello, Hector R Cajigas, Evan Brittain, Werner Seeger","doi":"10.1016/j.ebiom.2025.106063","DOIUrl":"10.1016/j.ebiom.2025.106063","url":null,"abstract":"<p><strong>Background: </strong>Sex-based differences in morbidity and mortality in pulmonary hypertension (PH) are underexplored, yet understanding these differences is vital for improving clinical management. This study investigates the influence of sex on survival of patients with PH in dependency of various disease conditions.</p><p><strong>Methods: </strong>The PVRI GoDeep meta-registry integrates data from international PH registries, of which we analysed 21,123 incident hemodynamically fully characterised patients with PH. Survival analyses employed Kaplan-Meier and Cox proportional hazards models, adjusted for confounders and subjected to sensitivity analyses.</p><p><strong>Findings: </strong>Male patients consistently showed significantly higher mortality than females across the overall PH population (hazard ratio 1.36 [1.23, 1.50] after adjustment) and within PAH and non-PAH groups. These sex differences in survival persisted regardless of P(A)H severities, age and obesity, cardiovascular diseases, and PAH-specific therapies. The male survival disadvantage was noted across low-, intermediate-, and high-risk groups of the ESC/ERS 2022, REVEAL lite 2, and COMPERA 4-strata scores, but not the REVEAL 2.0 risk score, which incorporates male sex as non-modifiable factor. Stratification by race revealed that male sex was associated with worse survival in White patients, but not in Black or Asian patients with PH.</p><p><strong>Interpretation: </strong>Male patients with PH exhibit significantly higher mortality risks than females across both PAH and non-PAH PH groups. This disparity persists regardless of PH severity, underlying cause, age, obesity, comorbidities, or treatment status, though race might modify the observed risk difference. These insights provide new avenues for investigating underlying mechanisms and suggest including male sex as an independent factor in clinical risk assessment tools.</p><p><strong>Funding: </strong>This work is funded by the Pulmonary Vascular Research Institute (PVRI) and the Cardiovascular Medical Research and Education Fund (CMREF), NIH.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106063"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12768861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial transcriptomics uncovers lipid metabolic dysregulation driving immune-stroma crosstalk in Sjögren's Disease. 空间转录组学揭示了Sjögren疾病中驱动免疫基质串扰的脂质代谢失调。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2025-12-17 DOI: 10.1016/j.ebiom.2025.106074
Shasha Li, Yan Liu, Haoshan Zhang, Simin Xu, Xiuzhen Wen, Yanhua Tang, Nana Zhang, David A Fox, Yanming Chen, Yunfeng Pan, Chenyang Lu

Background: Sjögren's Disease (SjD) is a systemic autoimmune disorder characterised by exocrine gland dysfunction and immune infiltration. However, the spatial cellular architecture and metabolic-immune crosstalk underlying glandular pathology in SjD remain unclear.

Methods: We performed spatial transcriptomics on SjD salivary glands (SGs) and conducted integrative analyses with single-cell RNA sequencing to delineate disease-specific transcriptomic alterations, followed by validation in an independent cohort. Key findings were verified via immunofluorescence, immunohistochemistry, and function assays on cells.

Findings: Spatial clustering revealed distinct perturbations in SjD. We identified a pathogenic CCL2high fibroblast-ACKR1high endothelial cell axis that co-localised in lymphoid foci and correlated with immune infiltration and disease activity. Chemokine-receptor axes were associated with immune infiltration, with endothelial ACKR1 facilitating inflammatory niche organisation. Compartmentalised immune-stroma niches exhibited upregulated phospholipid, glycerophospholipid and phosphatidylinositol metabolism in lymphoid foci, correlating with B/T-cell activation and interferon responses. Key metabolic regulators (PIK3CD, PIK3CG, PIKFYVE, and PLCG2) were elevated in SjD, associated with CD45+ cell abundance in SGs, and exhibited diagnostic potential. Conversely, epithelial cells showed suppressed glycerolipid metabolism and decreased MGLL expression, linked to enhanced antigen presentation. Inhibiting monoacylglycerol lipase (encoded by MGLL) upregulates MHC in A253 cells, while interferon-γ suppresses MGLL expression.

Interpretation: Our study elucidates spatially organised metabolic-immune networks in SjD, implicating lipid metabolism in immune activation and epithelial metabolic reprogramming in secretory dysfunction, nominating promising therapeutic targets.

Funding: National Natural Science Foundation of China (82104484,32301084), Joint funding from schools (colleges) and enterprises in Guangzhou (2025A03J3203, 2024A03J0987), Natural Science Foundation of Guangdong Province (2023A1515012790), Guangdong Provincial Enterprise Joint Fund (2022A1515220003), and Sun Yat-sen University (P02523).

背景:Sjögren's Disease (SjD)是一种以外分泌腺功能障碍和免疫浸润为特征的系统性自身免疫性疾病。然而,SjD腺体病理背后的空间细胞结构和代谢免疫串扰尚不清楚。方法:我们对SjD唾液腺(SGs)进行了空间转录组学研究,并利用单细胞RNA测序进行了综合分析,以描绘疾病特异性转录组改变,随后在独立队列中进行了验证。通过免疫荧光、免疫组织化学和细胞功能分析验证了关键发现。结果:空间聚类显示明显的SjD扰动。我们发现了一种致病性ccl2高成纤维细胞- ackr1高内皮细胞轴,它共定位于淋巴灶,并与免疫浸润和疾病活性相关。趋化因子受体轴与免疫浸润相关,内皮ACKR1促进炎症生态位组织。区隔化免疫基质龛在淋巴灶中表现出磷脂、甘油磷脂和磷脂酰肌醇代谢上调,与B/ t细胞活化和干扰素反应相关。关键代谢调节因子(PIK3CD、PIK3CG、PIKFYVE和PLCG2)在SjD中升高,与SGs中CD45+细胞丰度相关,具有诊断潜力。相反,上皮细胞表现出甘油脂代谢抑制和MGLL表达减少,这与抗原呈递增强有关。抑制单酰基甘油脂肪酶(由MGLL编码)上调A253细胞的MHC,而干扰素-γ抑制MGLL的表达。解释:我们的研究阐明了SjD中有空间组织的代谢-免疫网络,涉及免疫激活中的脂质代谢和分泌功能障碍中的上皮代谢重编程,提出了有希望的治疗靶点。项目资助:国家自然科学基金项目(82104484,32301084),广州市校企联合基金项目(2025A03J3203, 2024A03J0987),广东省自然科学基金项目(2023A1515012790),广东省企业联合基金项目(2022A1515220003),中山大学项目(P02523)。
{"title":"Spatial transcriptomics uncovers lipid metabolic dysregulation driving immune-stroma crosstalk in Sjögren's Disease.","authors":"Shasha Li, Yan Liu, Haoshan Zhang, Simin Xu, Xiuzhen Wen, Yanhua Tang, Nana Zhang, David A Fox, Yanming Chen, Yunfeng Pan, Chenyang Lu","doi":"10.1016/j.ebiom.2025.106074","DOIUrl":"10.1016/j.ebiom.2025.106074","url":null,"abstract":"<p><strong>Background: </strong>Sjögren's Disease (SjD) is a systemic autoimmune disorder characterised by exocrine gland dysfunction and immune infiltration. However, the spatial cellular architecture and metabolic-immune crosstalk underlying glandular pathology in SjD remain unclear.</p><p><strong>Methods: </strong>We performed spatial transcriptomics on SjD salivary glands (SGs) and conducted integrative analyses with single-cell RNA sequencing to delineate disease-specific transcriptomic alterations, followed by validation in an independent cohort. Key findings were verified via immunofluorescence, immunohistochemistry, and function assays on cells.</p><p><strong>Findings: </strong>Spatial clustering revealed distinct perturbations in SjD. We identified a pathogenic CCL2<sup>high</sup> fibroblast-ACKR1<sup>high</sup> endothelial cell axis that co-localised in lymphoid foci and correlated with immune infiltration and disease activity. Chemokine-receptor axes were associated with immune infiltration, with endothelial ACKR1 facilitating inflammatory niche organisation. Compartmentalised immune-stroma niches exhibited upregulated phospholipid, glycerophospholipid and phosphatidylinositol metabolism in lymphoid foci, correlating with B/T-cell activation and interferon responses. Key metabolic regulators (PIK3CD, PIK3CG, PIKFYVE, and PLCG2) were elevated in SjD, associated with CD45<sup>+</sup> cell abundance in SGs, and exhibited diagnostic potential. Conversely, epithelial cells showed suppressed glycerolipid metabolism and decreased MGLL expression, linked to enhanced antigen presentation. Inhibiting monoacylglycerol lipase (encoded by MGLL) upregulates MHC in A253 cells, while interferon-γ suppresses MGLL expression.</p><p><strong>Interpretation: </strong>Our study elucidates spatially organised metabolic-immune networks in SjD, implicating lipid metabolism in immune activation and epithelial metabolic reprogramming in secretory dysfunction, nominating promising therapeutic targets.</p><p><strong>Funding: </strong>National Natural Science Foundation of China (82104484,32301084), Joint funding from schools (colleges) and enterprises in Guangzhou (2025A03J3203, 2024A03J0987), Natural Science Foundation of Guangdong Province (2023A1515012790), Guangdong Provincial Enterprise Joint Fund (2022A1515220003), and Sun Yat-sen University (P02523).</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106074"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12774687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145780598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breastfeeding, bonding, and olfaction: unlocking the potential of mother-infant odour exchange. 母乳喂养,结合和嗅觉:释放母婴气味交换的潜力。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2025-12-20 DOI: 10.1016/j.ebiom.2025.106086
S Craig Roberts, Fabrice Damon, Karine Durand, Jan Havlíček, Dimitrios Kourtis, Ben Langford, Agnieszka Sorokowska, Piotr Sorokowski, Vivien Swanson, Jonathan Williams, Tatjana Arnoldi-Meadows, Dylan Brimaud, Daniela Dlouhá, Lucie Jelínková, Šárka Kaňková, Lenka Kapicová, Alice C Poirier, Kateřina Roberts, Justus C Sander, Dagmar Schwambergová, Michaela Silvestri, Nijing Wang, Emmanuel Simon, Benoist Schaal

Breastfeeding is crucial for infant survival, growth, and health, and it enhances maternal-infant bonding and well-being. However, breastfeeding rates typically fall below international targets, partly due to a high prevalence of latching difficulties, intermittent sucking, refusing the breast, or poor milk supply. Here, we propose that such uniquely human difficulties might be ameliorated by recognising, understanding, and facilitating the olfactory mechanisms that, in other mammals, regulate breastfeeding initiation and maternal-infant relationships in the first weeks of life. We briefly review evidence that odour mediates nipple-searching and suckling behaviour in other species, summarise the comparable evidence in humans, and outline pathways that could potentially reap hitherto unrealised benefits of olfactory communication between human mothers and neonates. We argue that enhanced awareness of such odour exchange could inform and enable changes in both policy and practice that might improve breastfeeding success and maternal-infant bonding, ultimately contributing to reduced infant mortality worldwide.

母乳喂养对婴儿的生存、成长和健康至关重要,并能增强母婴关系和幸福感。然而,母乳喂养率通常低于国际目标,部分原因是哺乳困难、间歇性吸吮、拒绝母乳或母乳供应不足的发生率很高。在这里,我们提出,通过认识、理解和促进其他哺乳动物在生命最初几周调节母乳喂养开始和母婴关系的嗅觉机制,人类可能会改善这种独特的困难。我们简要回顾了气味在其他物种中介导乳头搜索和哺乳行为的证据,总结了人类的类似证据,并概述了人类母亲和新生儿之间嗅觉交流迄今为止尚未实现的潜在益处的途径。我们认为,加强对这种气味交换的认识,可以告知并推动政策和实践的变化,从而提高母乳喂养的成功率和母婴关系,最终有助于降低全球婴儿死亡率。
{"title":"Breastfeeding, bonding, and olfaction: unlocking the potential of mother-infant odour exchange.","authors":"S Craig Roberts, Fabrice Damon, Karine Durand, Jan Havlíček, Dimitrios Kourtis, Ben Langford, Agnieszka Sorokowska, Piotr Sorokowski, Vivien Swanson, Jonathan Williams, Tatjana Arnoldi-Meadows, Dylan Brimaud, Daniela Dlouhá, Lucie Jelínková, Šárka Kaňková, Lenka Kapicová, Alice C Poirier, Kateřina Roberts, Justus C Sander, Dagmar Schwambergová, Michaela Silvestri, Nijing Wang, Emmanuel Simon, Benoist Schaal","doi":"10.1016/j.ebiom.2025.106086","DOIUrl":"10.1016/j.ebiom.2025.106086","url":null,"abstract":"<p><p>Breastfeeding is crucial for infant survival, growth, and health, and it enhances maternal-infant bonding and well-being. However, breastfeeding rates typically fall below international targets, partly due to a high prevalence of latching difficulties, intermittent sucking, refusing the breast, or poor milk supply. Here, we propose that such uniquely human difficulties might be ameliorated by recognising, understanding, and facilitating the olfactory mechanisms that, in other mammals, regulate breastfeeding initiation and maternal-infant relationships in the first weeks of life. We briefly review evidence that odour mediates nipple-searching and suckling behaviour in other species, summarise the comparable evidence in humans, and outline pathways that could potentially reap hitherto unrealised benefits of olfactory communication between human mothers and neonates. We argue that enhanced awareness of such odour exchange could inform and enable changes in both policy and practice that might improve breastfeeding success and maternal-infant bonding, ultimately contributing to reduced infant mortality worldwide.</p>","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106086"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12795994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyroid hormones and breast cancer: untangling the association. 甲状腺激素和乳腺癌:解开关系。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2025-12-23 DOI: 10.1016/j.ebiom.2025.106089
Italo Fernandes, Jessica G Cockburn, Steven A Narod, Katarzyna J Jerzak
{"title":"Thyroid hormones and breast cancer: untangling the association.","authors":"Italo Fernandes, Jessica G Cockburn, Steven A Narod, Katarzyna J Jerzak","doi":"10.1016/j.ebiom.2025.106089","DOIUrl":"10.1016/j.ebiom.2025.106089","url":null,"abstract":"","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106089"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12800640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: "Decreased T helper 1 cell function underlies recurrent sinopulmonary infections in the 17q12 deletion syndrome" EBioMedicine, 2025, Feb:112:105578. 更正:“T辅助性1细胞功能降低是17q12缺失综合征复发性肺感染的基础”,EBioMedicine, 2025, Feb:112:105578。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2025-12-24 DOI: 10.1016/j.ebiom.2025.106095
Junghee J Shin, Hyeon Jun Shin, Alan Gutierrez, Noelle Yoo, Jennefer Par-Young, Lais Osmani, Min Sun Shin, Pedro A Sanchez-Lara, Richard Bucala, Gary Soffer, Insoo Kang
{"title":"Corrigendum: \"Decreased T helper 1 cell function underlies recurrent sinopulmonary infections in the 17q12 deletion syndrome\" EBioMedicine, 2025, Feb:112:105578.","authors":"Junghee J Shin, Hyeon Jun Shin, Alan Gutierrez, Noelle Yoo, Jennefer Par-Young, Lais Osmani, Min Sun Shin, Pedro A Sanchez-Lara, Richard Bucala, Gary Soffer, Insoo Kang","doi":"10.1016/j.ebiom.2025.106095","DOIUrl":"10.1016/j.ebiom.2025.106095","url":null,"abstract":"","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106095"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12799761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy. 在伴有周围神经病变的2型糖尿病患者的2a期研究中,局部应用抗uscarinic匹伦泽平可增加下肢神经纤维密度。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2025-12-05 DOI: 10.1016/j.ebiom.2025.106055
Ajith Sivadasan, Paul Fernyhough, Nigel A Calcutt, Katie E Frizzi, Kimberly Gardner, Angela Hansen, Ari Breiner, Douglas W Zochodne, Natalia McInnes, Zubin Punthakee, Sylvie Gosselin, Bruce A Perkins, Vera Bril
<p><strong>Background: </strong>There is no effective definitive treatment for diabetic peripheral neuropathy (DPN). Strategies that target nerve pathology, limit nerve degeneration, and promote axon regeneration can potentially be beneficial. Topical pirenzepine promotes nerve fibre protection and repair in rodent models of type 1 and type 2 diabetes. We assessed the efficacy and safety of topical pirenzepine for the treatment of DPN.</p><p><strong>Methods: </strong>Preclinical studies were performed to determine efficacy of a topical formulation of 4% pirenzepine against indices of neuropathy in adult female Sprague-Dawley rats with streptozotocin (STZ)-induced diabetes. We then did a proof-of-concept randomised Phase 2a, double-blind, placebo-controlled, clinical trial conducted across 5 university centres in Canada. Participants (aged 18-75 years) with definite type-2 DPN, as defined by the Toronto Consensus Guidelines, who were on stable anti-diabetic and analgesic therapy prior to screening and during the study were enrolled. Participants were randomised to 1 of 4 treatment groups in a 1:1:4:4 ratio, where placebo (2 mL), placebo (4 mL); pirenzepine (2 mL of 4% formulation); and pirenzepine (4 mL of 4% formulation) were self-administered topically by the participants for a 24 weeks period. Safety and tolerability of 2 dose levels of 4% pirenzepine for 24 weeks was the primary objective. The primary efficacy endpoints were the change at 24 weeks from baseline in the intraepidermal nerve fibre density (IENFD) collected from the treated skin (ankle) and the impact on the Norfolk-quality of life-diabetic neuropathy (QOL-DN). Punch biopsies (3 mm) were collected and shipped to a centralised facility for processing and reading. The trial was approved by Health Canada (226063) and registered with ClinicalTrials.govNCT04005287.</p><p><strong>Findings: </strong>In rats, topically administered 4% pirenzepine (100 μl) to the hind paws applied 5 days per week for 6 weeks of diabetes prevented large fibre conduction slowing, touch-evoked allodynia, reduced mean axonal diameter, and small fibre mediated heat hypoalgesia and cold hyperalgesia. Two doses of topical pirenzepine or placebo were administered to 58 DPN individuals for 24 weeks, between October 15, 2019 and December 15, 2021. The least squares mean difference in change from baseline to week 24 in the IENFD at the ankle was 2.32 (p = 0.006) in the pirenzepine 4 mL group; 1.50 (p = 0.048) in the pirenzepine 2 mL group and -0.71 (p = 0.39) in placebo patients on the modified-intent-to-treat analysis (mITT). The change in IENFD at the ankle was significant in the combined pirenzepine groups compared to placebo (p = 0.012). No differences were observed in other parameters in the mITT population. There was a 10.4-point improvement in the Norfolk QOL-DN score in the combined treatment groups over placebo (p < 0.001) in the per protocol (PP) analysis set, but no difference was observed in the modified
背景:糖尿病周围神经病变(DPN)尚无有效的明确治疗方法。针对神经病理,限制神经变性,促进轴突再生的策略可能是有益的。局部吡仑西平促进1型和2型糖尿病啮齿动物模型的神经纤维保护和修复。我们评估了外用吡仑西平治疗DPN的有效性和安全性。方法:采用临床前研究方法,观察4%吡仑西平外用制剂对STZ诱导的糖尿病成年雌性sd大鼠神经病变指标的影响。然后,我们在加拿大的5所大学中心进行了一项概念验证随机2a期,双盲,安慰剂对照的临床试验。参与者(年龄18-75岁)明确患有多伦多共识指南定义的2型DPN,在筛查前和研究期间接受稳定的抗糖尿病和镇痛治疗。参与者按1:1:4:4的比例随机分配到4个治疗组中的1个,其中安慰剂(2 mL),安慰剂(4 mL);吡伦齐平(2ml 4%配方);和吡仑西平(4ml 4%配方)由参与者自行局部给药,为期24周。2个剂量水平的4%吡仑西平24周的安全性和耐受性是主要目标。主要疗效终点是从治疗皮肤(踝关节)收集的表皮内神经纤维密度(IENFD)与基线相比24周的变化以及对诺福克-生活质量(糖尿病神经病变)的影响。收集穿孔活检(3毫米)并运送到集中设施进行处理和读取。该试验已获得加拿大卫生部批准(226063),并在clinicaltrials . govnct04005287上注册。研究结果:在大鼠中,每周5天,局部给予4%吡伦西平(100 μl)于后爪,连续6周治疗糖尿病,可防止大纤维传导减慢、触摸诱发的异常性疼痛、平均轴突直径减小、小纤维介导的热痛觉减退和冷痛觉过敏。在2019年10月15日至2021年12月15日期间,58名DPN患者接受了两种剂量的局部吡renzepine或安慰剂治疗,持续24周。吡仑西平4 mL组踝关节IENFD从基线到第24周变化的最小二乘平均差为2.32 (p = 0.006);改良意向治疗分析(改良意向治疗分析)中,匹伦齐平2 mL组为1.50 (p = 0.048),安慰剂组为-0.71 (p = 0.39)。与安慰剂组相比,联合使用吡仑西平组踝关节的IENFD变化显著(p = 0.012)。在mITT人群中,其他参数没有观察到差异。在每个方案(PP)分析集中,联合治疗组的Norfolk QOL-DN评分比安慰剂提高了10.4分(p < 0.001),但在改进的意向治疗分析中没有观察到差异,这表明由于潜在的偏倚,需要谨慎解释PP结果。与研究药物可能/可能/明确相关的全身不良事件在治疗组之间相似。给药部位反应是吡伦平治疗组中最常见的治疗紧急不良事件(吡伦平4ml 41.7%,吡伦平2ml 22.6%,安慰剂8.3%)。没有人员死亡。解释:临床前研究中外用吡伦齐平的疗效转化为临床研究。患者组之间的整体系统安全性概况相似。然而,局部局部反应在活性剂量组比安慰剂组更普遍。通过IENFD测量,DPN患者在脚踝处的神经纤维生长具有统计学意义。这项针对DPN患者的研究表明,选择性靶向毒蕈碱乙酰胆碱1型受体可促进远端轴突的再生。未来的2b期和3期研究需要证实这些观察结果。资助:本研究由CIHR、马尼托巴研究中心和WinSanTor资助。
{"title":"Topical application of the antimuscarinic pirenzepine increased lower limb nerve fibre density in a phase 2a study in type 2 patients with diabetes with peripheral neuropathy.","authors":"Ajith Sivadasan, Paul Fernyhough, Nigel A Calcutt, Katie E Frizzi, Kimberly Gardner, Angela Hansen, Ari Breiner, Douglas W Zochodne, Natalia McInnes, Zubin Punthakee, Sylvie Gosselin, Bruce A Perkins, Vera Bril","doi":"10.1016/j.ebiom.2025.106055","DOIUrl":"10.1016/j.ebiom.2025.106055","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;There is no effective definitive treatment for diabetic peripheral neuropathy (DPN). Strategies that target nerve pathology, limit nerve degeneration, and promote axon regeneration can potentially be beneficial. Topical pirenzepine promotes nerve fibre protection and repair in rodent models of type 1 and type 2 diabetes. We assessed the efficacy and safety of topical pirenzepine for the treatment of DPN.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Preclinical studies were performed to determine efficacy of a topical formulation of 4% pirenzepine against indices of neuropathy in adult female Sprague-Dawley rats with streptozotocin (STZ)-induced diabetes. We then did a proof-of-concept randomised Phase 2a, double-blind, placebo-controlled, clinical trial conducted across 5 university centres in Canada. Participants (aged 18-75 years) with definite type-2 DPN, as defined by the Toronto Consensus Guidelines, who were on stable anti-diabetic and analgesic therapy prior to screening and during the study were enrolled. Participants were randomised to 1 of 4 treatment groups in a 1:1:4:4 ratio, where placebo (2 mL), placebo (4 mL); pirenzepine (2 mL of 4% formulation); and pirenzepine (4 mL of 4% formulation) were self-administered topically by the participants for a 24 weeks period. Safety and tolerability of 2 dose levels of 4% pirenzepine for 24 weeks was the primary objective. The primary efficacy endpoints were the change at 24 weeks from baseline in the intraepidermal nerve fibre density (IENFD) collected from the treated skin (ankle) and the impact on the Norfolk-quality of life-diabetic neuropathy (QOL-DN). Punch biopsies (3 mm) were collected and shipped to a centralised facility for processing and reading. The trial was approved by Health Canada (226063) and registered with ClinicalTrials.govNCT04005287.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;In rats, topically administered 4% pirenzepine (100 μl) to the hind paws applied 5 days per week for 6 weeks of diabetes prevented large fibre conduction slowing, touch-evoked allodynia, reduced mean axonal diameter, and small fibre mediated heat hypoalgesia and cold hyperalgesia. Two doses of topical pirenzepine or placebo were administered to 58 DPN individuals for 24 weeks, between October 15, 2019 and December 15, 2021. The least squares mean difference in change from baseline to week 24 in the IENFD at the ankle was 2.32 (p = 0.006) in the pirenzepine 4 mL group; 1.50 (p = 0.048) in the pirenzepine 2 mL group and -0.71 (p = 0.39) in placebo patients on the modified-intent-to-treat analysis (mITT). The change in IENFD at the ankle was significant in the combined pirenzepine groups compared to placebo (p = 0.012). No differences were observed in other parameters in the mITT population. There was a 10.4-point improvement in the Norfolk QOL-DN score in the combined treatment groups over placebo (p &lt; 0.001) in the per protocol (PP) analysis set, but no difference was observed in the modified ","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106055"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12721300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody. 抗核蛋白hRSV单克隆抗体保护能力的临床前特征。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2026-01-02 DOI: 10.1016/j.ebiom.2025.106104
Mónica A Farías, Catalina A Andrade, Ricardo A Loaiza, Linmar Rodríguez-Guilarte, José T Muñoz, Patricia Pereira-Sánchez, Natalia Muñoz-Durango, Magdalena S Pizarro-Ortega, Benjamín Diethelm-Varela, Alejandra Pereira-Serrano, Robinson A Ramírez, José L Chávez, Karen Bohmwald, Jorge A Soto, Pablo A González, Susan M Bueno, Alexis M Kalergis
<p><strong>Background: </strong>The human respiratory syncytial virus (hRSV) is a pathogen of global concern, causing significant morbidity and mortality, mainly in preterm infants. To date, all licenced monoclonal antibodies (mAbs) developed against hRSV have targeted its surface fusion or pre-fusion protein (F-hRSV).</p><p><strong>Methods: </strong>We developed mAbs against the hRSV nucleoprotein (N-hRSV) as a complementary prophylactic treatment. Firstly, we produced a humanised murine mAb against N-hRSV, yielding four clones. Antibody affinity assays against the N-hRSV protein, pharmacokinetic analyses, and protection assays against pulmonary and neurological pathologies associated with hRSV infection in an in vivo male and female BALB/c murine model were performed. In vitro assays were carried out to determine the mechanisms of action of the humanised anti-N-hRSV mAbs, which exhibit antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).</p><p><strong>Findings: </strong>Four humanised anti-N-hRSV mAb clones (P1-04H, P1-05D, P2-01A and P2-01D) were purified and showed high affinity for N-hRSV protein, as determined by SDS-PAGE and surface plasmon resonance, respectively. Pharmacokinetic analyses showed that two clones were detectable in the animals up to 30 days post-immunisation. Furthermore, treating mice with the humanised anti-N-hRSV mAb 1 day before hRSV infection reduced weight loss (P1-05D, ∗∗p = 0.0069; and P2-01D, p = 0.0875), clinical score (P1-05D, ∗∗p = 0.0052; P2-01A, ∗p = 0.04; P2-01D, ∗∗∗∗p < 0.0001), and pulmonary N-hRSV mRNA expression levels in hRSV serotype A-infected mice (P2-01A, p = 0.0612; P2-01D, p < 0.0613), while all animals infected with hRSV serotype B showed reduced levels of N-hRSV expression (P1-04H, ∗∗p = 0.0022; P1-05D, ∗∗p = 0.0013; P2-01A, ∗∗p = 0.0013; and P2-01D, ∗∗p = 0.0013). Brain viral load was also decreased (P1-04H; P1-05D; P2-01A; and P2-01D, ∗∗∗∗p < 0.0001). 30 days post-infection, behavioural tests indicated protection against long-term neurological alterations, with reduced faecal boli (P1-04H; and P2-01D, ∗p = 0.0243), altered centre preference (P1-04H; P1-05D; and P2-01D, ∗∗∗∗p < 0.0001), and restoration of marble burying behaviour (clone P2-01D, ∗∗p = 0.0055). Finally, in vitro analyses showed that the humanised anti-N-hRSV mAb displayed ADCC and CDC mechanisms to target infected cells.</p><p><strong>Interpretation: </strong>Our findings suggest that the humanised N-hRSV-specific mAbs displayed promising preclinical profiles by protecting against the pathology caused by hRSV infection.</p><p><strong>Funding: </strong>This study was supported by funding from the Millennium Institute on Immunology and Immunotherapy ANID ACE 210015 (CN09_016/ICN 2021_045; former P09/016-F, AMK); Biomedical Research Consortium CTU06 (AMK); FONDEF ID22I10252 (AMK and SMB); Fundación COPEC-UC 2019.R.1169 (AMK); FONDECYT Regular grant #1231866 (JAS), #1240971 (PAG), #1231905 (SMB)
背景:人呼吸道合胞病毒(hRSV)是一种引起全球关注的病原体,其发病率和死亡率很高,主要发生在早产儿中。迄今为止,所有获得许可的针对hRSV的单克隆抗体(mab)都针对其表面融合或预融合蛋白(F-hRSV)。方法:我们开发了针对hRSV核蛋白(N-hRSV)的单克隆抗体,作为预防治疗的补充。首先,我们制备了一种人源化的抗N-hRSV小鼠单抗,获得了4个克隆。在体内雄性和雌性BALB/c小鼠模型中进行了针对N-hRSV蛋白的抗体亲和分析、药代动力学分析以及对与hRSV感染相关的肺部和神经病变的保护试验。体外实验确定了人源抗n - hrsv单克隆抗体的作用机制,其表现出抗体依赖性细胞毒性(ADCC)和补体依赖性细胞毒性(CDC)。结果:纯化了4个人源抗N-hRSV单抗克隆(P1-04H, P1-05D, P2-01A和P2-01D),分别通过SDS-PAGE和表面等离子体共振检测,它们对N-hRSV蛋白具有高亲和力。药代动力学分析表明,在免疫后30天,在动物体内可检测到两个克隆。此外,在hRSV感染前1天用人源化抗N-hRSV单抗治疗小鼠,可降低hRSV a血清型感染小鼠的体重(P1-05D,∗∗p = 0.0069, P2-01D, p = 0.075)、临床评分(P1-05D,∗∗p = 0.0052; P2-01A,∗p = 0.04; P2-01D,∗∗p < 0.0001)和肺N-hRSV mRNA表达水平(P2-01A, p = 0.0612; P2-01D, p < 0.0613),而所有感染hRSV B血清型的小鼠均表现出N-hRSV表达水平降低(P1-04H,∗∗p = 0.0022; P1-05D,∗∗p = 0.0013;P2-01A, * * p = 0.0013;P2-01D,∗∗p = 0.0013)。脑病毒载量也降低(P1-04H; P1-05D; P2-01A; P2-01D,∗∗∗p < 0.0001)。感染后30天,行为测试显示对长期神经系统改变有保护作用,粪粪减少(P1-04H和P2-01D,∗p = 0.0243),中心偏好改变(P1-04H; P1-05D和P2-01D,∗∗p < 0.0001),大理石掩埋行为恢复(克隆P2-01D,∗∗p = 0.0055)。最后,体外分析表明,人源化抗n - hrsv单抗对感染细胞具有ADCC和CDC机制。解释:我们的研究结果表明,人源化的n -hRSV特异性单克隆抗体显示出有希望的临床前特征,可以预防hRSV感染引起的病理。本研究由千年免疫与免疫治疗研究所ANID ACE 210015 (CN09_016/ICN 2021_045;原P09/016-F, AMK)资助;生物医学研究联盟CTU06 (AMK);FONDEF ID22I10252 (AMK和SMB);Fundación COPEC-UC 2019.R.1169(AMK);常规拨款#1231866 (JAS), #1240971 (PAG), #1231905 (SMB), #1190830和#1231851 (AMK)。FONDECYT Iniciación grant #11221280 (KB)。ANID FONDECYT博士后资助#3240624 (MAF)。ANID奖学金#21210662 (CAP), #21251811 (RAL), #21230429 (LRG), #21242058 (JTM)和#21221163 (BDV)。
{"title":"Preclinical characterisation of the protective capacity of an anti-nucleoprotein hRSV monoclonal antibody.","authors":"Mónica A Farías, Catalina A Andrade, Ricardo A Loaiza, Linmar Rodríguez-Guilarte, José T Muñoz, Patricia Pereira-Sánchez, Natalia Muñoz-Durango, Magdalena S Pizarro-Ortega, Benjamín Diethelm-Varela, Alejandra Pereira-Serrano, Robinson A Ramírez, José L Chávez, Karen Bohmwald, Jorge A Soto, Pablo A González, Susan M Bueno, Alexis M Kalergis","doi":"10.1016/j.ebiom.2025.106104","DOIUrl":"10.1016/j.ebiom.2025.106104","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The human respiratory syncytial virus (hRSV) is a pathogen of global concern, causing significant morbidity and mortality, mainly in preterm infants. To date, all licenced monoclonal antibodies (mAbs) developed against hRSV have targeted its surface fusion or pre-fusion protein (F-hRSV).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We developed mAbs against the hRSV nucleoprotein (N-hRSV) as a complementary prophylactic treatment. Firstly, we produced a humanised murine mAb against N-hRSV, yielding four clones. Antibody affinity assays against the N-hRSV protein, pharmacokinetic analyses, and protection assays against pulmonary and neurological pathologies associated with hRSV infection in an in vivo male and female BALB/c murine model were performed. In vitro assays were carried out to determine the mechanisms of action of the humanised anti-N-hRSV mAbs, which exhibit antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Findings: &lt;/strong&gt;Four humanised anti-N-hRSV mAb clones (P1-04H, P1-05D, P2-01A and P2-01D) were purified and showed high affinity for N-hRSV protein, as determined by SDS-PAGE and surface plasmon resonance, respectively. Pharmacokinetic analyses showed that two clones were detectable in the animals up to 30 days post-immunisation. Furthermore, treating mice with the humanised anti-N-hRSV mAb 1 day before hRSV infection reduced weight loss (P1-05D, ∗∗p = 0.0069; and P2-01D, p = 0.0875), clinical score (P1-05D, ∗∗p = 0.0052; P2-01A, ∗p = 0.04; P2-01D, ∗∗∗∗p &lt; 0.0001), and pulmonary N-hRSV mRNA expression levels in hRSV serotype A-infected mice (P2-01A, p = 0.0612; P2-01D, p &lt; 0.0613), while all animals infected with hRSV serotype B showed reduced levels of N-hRSV expression (P1-04H, ∗∗p = 0.0022; P1-05D, ∗∗p = 0.0013; P2-01A, ∗∗p = 0.0013; and P2-01D, ∗∗p = 0.0013). Brain viral load was also decreased (P1-04H; P1-05D; P2-01A; and P2-01D, ∗∗∗∗p &lt; 0.0001). 30 days post-infection, behavioural tests indicated protection against long-term neurological alterations, with reduced faecal boli (P1-04H; and P2-01D, ∗p = 0.0243), altered centre preference (P1-04H; P1-05D; and P2-01D, ∗∗∗∗p &lt; 0.0001), and restoration of marble burying behaviour (clone P2-01D, ∗∗p = 0.0055). Finally, in vitro analyses showed that the humanised anti-N-hRSV mAb displayed ADCC and CDC mechanisms to target infected cells.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interpretation: &lt;/strong&gt;Our findings suggest that the humanised N-hRSV-specific mAbs displayed promising preclinical profiles by protecting against the pathology caused by hRSV infection.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Funding: &lt;/strong&gt;This study was supported by funding from the Millennium Institute on Immunology and Immunotherapy ANID ACE 210015 (CN09_016/ICN 2021_045; former P09/016-F, AMK); Biomedical Research Consortium CTU06 (AMK); FONDEF ID22I10252 (AMK and SMB); Fundación COPEC-UC 2019.R.1169 (AMK); FONDECYT Regular grant #1231866 (JAS), #1240971 (PAG), #1231905 (SMB)","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106104"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12805088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145896405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-dependent diffusion MRI: clinical potential in renal transplantation. 时间依赖扩散MRI:肾移植的临床潜力。
IF 10.8 1区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2026-01-01 Epub Date: 2026-01-03 DOI: 10.1016/j.ebiom.2025.106115
Siria Pasini, Norberto Perico, Anna Caroli
{"title":"Time-dependent diffusion MRI: clinical potential in renal transplantation.","authors":"Siria Pasini, Norberto Perico, Anna Caroli","doi":"10.1016/j.ebiom.2025.106115","DOIUrl":"10.1016/j.ebiom.2025.106115","url":null,"abstract":"","PeriodicalId":11494,"journal":{"name":"EBioMedicine","volume":"123 ","pages":"106115"},"PeriodicalIF":10.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12805287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145899504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
EBioMedicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1